Loading…

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Saved in:

Bibliographic Details
Published in:	Blood 2022-11, Vol.140 (Supplement 1), p.397-399
Main Authors:	Carlo-Stella, Carmelo, Mazza, Rita, Manier, Salomon, Facon, Thierry, Yoon, Sung-Soo, Koh, Youngil, Harrison, Simon J, Er, Jeremy, Pinto, Antonio, Volzone, Francesco, Perrone, Giulia, Corradini, Paolo, Cazaubiel, Titouan, Hulin, Cyrille, Touzeau, Cyrille, Moreau, Philippe, Ocio, Enrique M., Montes Gaisan, Carmen Maria, Popat, Rakesh, Leong, Sarah, Offner, Fritz, Rodriguez Otero, Paula, Alfonso-Pierola, Ana, Bröske, Ann-Marie E, Dekhtiarenko, Iryna, Helms, Hans-Joachim, Belli, Sara, Rossmann, Eva, Fauti, Tanja, Eckmann, Jan, Moore, Tom, Schneider, Meike, Jacob, Wolfgang, Weisser, Martin, Hutchings, Martin, Riley, Caroline Hasselbalch
Format:	Article
Language:	English
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!